{"id":"agn-199201-dose-a","safety":{"commonSideEffects":[{"rate":null,"effect":"Testosterone suppression"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Acne"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a SARM, AGN-199201 binds to and activates the androgen receptor with tissue-selective activity, potentially providing anabolic effects in muscle and bone while minimizing androgenic side effects in other tissues. This selective activation profile is designed to improve muscle function and physical performance in conditions where androgen signaling is beneficial.","oneSentence":"AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:20:20.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting or sarcopenia (phase 2 development)"}]},"trialDetails":[{"nctId":"NCT02595528","phase":"PHASE2","title":"A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-04-29","conditions":"Presbyopia","enrollment":163},{"nctId":"NCT02780115","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-05-26","conditions":"Presbyopia","enrollment":151},{"nctId":"NCT01735201","phase":"PHASE2","title":"AGN-199201 for the Treatment of Erythema With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-12","conditions":"Rosacea, Erythema","enrollment":357}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-199201 Dose A","genericName":"AGN-199201 Dose A","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-199201 is a selective androgen receptor modulator (SARM) that activates androgen signaling in target tissues. Used for Muscle wasting or sarcopenia (phase 2 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}